The consumption of glucose by tumor limits T-cell metabolism, leading to the dampened glycolytic capacity, mTOR activity, and IFN-γ production, representing the adaptation of resistance to the MSI-induced immunoreactive microenvironment and thereby allowing tumor progression. This evidence concerns the gene MTOR and neoplasm.